Comparison of thromboembolic events in patients treated with Celecoxib, a Cyclooxygenase-2 specific inhibitor, versus Ibuprofen or Diclofenac
- 1 February 2002
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 89 (4), 425-430
- https://doi.org/10.1016/s0002-9149(01)02265-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJama-Journal Of The American Medical Association, 2001
- NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotectionThe Lancet, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJama-Journal Of The American Medical Association, 2000
- Basic biology and clinical application of specific cyclooxygenase-2 inhibitorsArthritis & Rheumatism, 2000
- Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid ArthritisJama-Journal Of The American Medical Association, 1999
- Potential utility of COX-2 inhibitors in chemoprevention and chemotherapyExpert Opinion on Investigational Drugs, 1999
- Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2Proceedings of the National Academy of Sciences of the United States of America, 1999
- Aspirin as a Therapeutic Agent in Cardiovascular DiseaseCirculation, 1997
- Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)Prostaglandins, 1989